Explore this article's sources with AI
Follow PeptideMethods on Google
Semaglutide in Two Very Young Children
A two-child case series reports lower BMI-SDS with semaglutide, but no control group and no approval for this preschool age range.
Why we wrote this. A report in two preschool-aged children needs a strict separation between measured case outcomes, uncontrolled observation and approved pediatric use.
In this article (6 sections)
A 2026 case report describes semaglutide treatment in two children aged 4.5 and 3.3 years with severe early-onset obesity. Their BMI standard deviation scores fell during 18 and 21 months of follow-up, respectively. This was an uncontrolled two-child case series, not a trial, so it cannot establish that semaglutide caused the changes or define treatment for children this young[1].
The first child had ADCY3-related obesity
The first case was a 4.5-year-old girl with a homozygous ADCY3 c.1102G>A variant. A homozygous variant means the same genetic change was present in both copies of the gene. The authors described severe obesity and hyperphagia, meaning persistent excessive hunger, along with hypertension, fatty liver disease, Blount's disease and left ventricular hypertrophy. Her baseline BMI was 48.0 kg/m², corresponding to a BMI-SDS of +5.5[1]. BMI-SDS expresses how far a child's BMI sits from the age-specific and sex-specific reference average. It is not the same measure as percentage body-weight change.
The report says semaglutide started at 0.125 mg weekly and was gradually increased to 1.5 mg weekly. After 18 months, her BMI-SDS was +4.1, down from +5.5. The authors calculated this as a 25.5% reduction in BMI-SDS. They also reported improved hyperphagia and resolution of left ventricular hypertrophy. Linear growth remained appropriate for age, and the report recorded no significant adverse effects[1]. Those doses describe one clinician-managed case. They are not a dosing schedule for another child.
The second child had Klinefelter syndrome
The second case was a 3.3-year-old boy with hyperphagia, severe obesity and dyslipidaemia. Testing identified Klinefelter syndrome, with a 47,XXY chromosome pattern. Clinical exome sequencing did not identify a genetic variant that explained his obesity, so the report does not classify his obesity as a confirmed monogenic disorder. His baseline BMI was 32.6 kg/m² and his BMI-SDS was +5.7[1].
The authors report that semaglutide began at 0.0625 mg weekly and was gradually increased to 2.0 mg weekly. After 21 months, his BMI-SDS was +4.4, a reported reduction of 22%. Treatment was described as generally well tolerated, and linear growth remained normal[1]. The abstract does not provide a detailed adverse-event table or specify how possible harms were collected. A statement that treatment was tolerated in one child cannot estimate the frequency of common or uncommon adverse events.
BMI-SDS fell, but causation remains open
Both children had lower BMI-SDS values at the end of observation, and neither showed impaired linear growth in the report. The first child also had reported changes in hunger and cardiac structure. These are measured or clinically observed outcomes within the two cases[1]. They do not show what would have happened without semaglutide. There was no control group, random assignment, blinding or prespecified comparison with another treatment.
The children also differed in age, genetic findings, baseline conditions, starting BMI, dose history and follow-up length. With only two participants, the report cannot separate a drug effect from clinical care, development over time or other unreported influences. It cannot estimate average benefit, identify which genetic forms of early-onset obesity might respond, or detect harms that occur infrequently.
The genetic distinction is especially relevant. Only the first child had a variant presented as causative for monogenic obesity. The second had Klinefelter syndrome, but exome sequencing found no obesity-causing variant. Combining their BMI-SDS changes does not create evidence for one shared genetic subgroup[1]. The authors appropriately call for evaluation in larger studies rather than treating two responses as a general result.
Evidence in adolescents does not fill the age gap
A randomized study provides stronger evidence for an older pediatric population. STEP TEENS enrolled 201 participants aged 12 to under 18 years with obesity or overweight plus a weight-related condition. Participants received semaglutide or placebo alongside lifestyle intervention for 68 weeks. Mean BMI changed by -16.1% with semaglutide and +0.6% with placebo. Gastrointestinal adverse events occurred in 62% and 42%, respectively, and cholelithiasis was reported in five semaglutide participants and none assigned to placebo[2].
That trial does not validate treatment in preschool-aged children. Its participants were at least 12 years old, it used a randomized comparison, and its primary outcome was percentage change in BMI. The case report involved children aged 3.3 and 4.5 years and reported change in BMI-SDS. The age range, design and outcome scale are different, so the adolescent result should not be applied to these two cases.
The current US label starts at age 12
The current US Wegovy label establishes safety and effectiveness for weight management in pediatric patients aged 12 years and older with obesity. It bases that pediatric indication on a 68-week placebo-controlled trial in 201 patients. The label does not establish a weight-management indication for children younger than 12, including children of preschool age[3]. Our semaglutide regulation section tracks the broader prescription and approval context.
The label also carries a boxed warning about thyroid C-cell tumors observed in rodents, with human relevance undetermined, and lists warnings concerning pancreatitis, gallbladder disease, kidney injury related to volume depletion and severe gastrointestinal reactions[3]. The case report's reassuring observations over 18 and 21 months do not remove those label-level concerns or answer long-term development and safety questions in very young children.
What a larger study would need to answer
A useful next study would define the genetic diagnoses before enrollment, use age-appropriate comparison care and prespecify BMI-SDS, height velocity, hunger measures, metabolic markers and adverse-event collection. It would also need enough participants and follow-up to examine whether changes persist and whether safety differs by age or genetic cause. The two published cases can help frame those questions, but they cannot answer them.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
How old were the children in the semaglutide case report?
One child was 4.5 years old and was followed for 18 months. The other was 3.3 years old and was followed for 21 months. The report included no control group.
What genetic diagnoses did the two children have?
The first child had a homozygous ADCY3 variant reported as a cause of monogenic obesity. The second had Klinefelter syndrome, while exome sequencing found no causative obesity variant.
Is semaglutide approved for obesity in children under 6?
No. The current US Wegovy label establishes pediatric weight-management use from age 12. This two-child case report does not extend that approval or establish a protocol for younger children.
Sources
- [1]Canbaz et al. Semaglutide treatment in two very young children with severe early-onset obesity. Hormone Research in Paediatrics. 2026. PMID 42912696.Tier 1 · primary↩
- [2]Weghuber et al. Once-weekly semaglutide in adolescents with obesity. New England Journal of Medicine. 2022. PMCID PMC9997064.Tier 1 · primary↩
- [3]Wegovy (semaglutide) US prescribing information. DailyMed. Revised June 2026.Tier 1 · primary↩
No revisions yet. First published .